Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Antares Pharma (ATRS) Stock Price

Media stories about Antares Pharma (NASDAQ:ATRS) have been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Antares Pharma earned a news impact score of 0.08 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 47.2032143187904 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of ATRS stock opened at $2.11 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.94 and a current ratio of 3.53. The firm has a market capitalization of $330.82, a PE ratio of -19.18 and a beta of 0.21. Antares Pharma has a 12 month low of $1.58 and a 12 month high of $4.09.

How to Become a New Pot Stock Millionaire

Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings data on Tuesday, March 13th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.01. The business had revenue of $14.00 million for the quarter, compared to analyst estimates of $15.44 million. Antares Pharma had a negative net margin of 30.71% and a negative return on equity of 44.29%. The business’s quarterly revenue was down 1.4% on a year-over-year basis. analysts anticipate that Antares Pharma will post -0.07 earnings per share for the current fiscal year.

A number of research analysts have weighed in on ATRS shares. BidaskClub raised shares of Antares Pharma from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd. HC Wainwright set a $4.00 price target on shares of Antares Pharma and gave the company a “buy” rating in a research note on Tuesday, March 27th. Finally, ValuEngine raised shares of Antares Pharma from a “sell” rating to a “hold” rating in a research report on Friday, March 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $3.94.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Antares Pharma (ATRS) Stock Price” was originally reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3341137/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-antares-pharma-atrs-stock-price.html.

About Antares Pharma

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Insider Buying and Selling by Quarter for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

O’Reilly Auto Parts  Upgraded to “Hold” at Zacks Investment Research
O’Reilly Auto Parts Upgraded to “Hold” at Zacks Investment Research
Verso  Lowered to Sell at Zacks Investment Research
Verso Lowered to Sell at Zacks Investment Research
Fortune Brands Home & Security  Downgraded by Zacks Investment Research to Sell
Fortune Brands Home & Security Downgraded by Zacks Investment Research to Sell
Noble  Trading 5.3% Higher
Noble Trading 5.3% Higher
NeoPhotonics   Shares Down 6.3%
NeoPhotonics Shares Down 6.3%
Fred’s  Trading Down 9.3%
Fred’s Trading Down 9.3%


Leave a Reply

© 2006-2018 Ticker Report. Google+.